Sangamo Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -47.5% | -47.5% | -24.7% |
| FY2022 | -65.2% | -65.2% | -34.2% |
| FY2023 | -311.1% | -311.1% | -156.0% |
| FY2024 | -430.1% | -430.1% | -96.4% |
| FY2025 | 861.6% | 861.6% | -205.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -47.5% | -47.5% | -24.7% |
| FY2022 | -65.2% | -65.2% | -34.2% |
| FY2023 | -311.1% | -311.1% | -156.0% |
| FY2024 | -430.1% | -430.1% | -96.4% |
| FY2025 | 861.6% | 861.6% | -205.8% |